Hideki Narumi
Overview
Explore the profile of Hideki Narumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
47
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chon H, Kanamori S, Hibino K, Nagahara T, Suzuki T, Ohara K, et al.
Bioorg Med Chem Lett
. 2022 Dec;
80:129117.
PMID: 36584791
The conserved N-linked glycan at the Fc domain of recombinant monoclonal antibodies is an attractive target for site-specific payload conjugation for preparation of homogenous antibody-drug conjugates (ADCs). Here, we report...
2.
Yokokawa H, Shinohara M, Teraoka Y, Imamura M, Nakamura N, Watanabe N, et al.
PLoS One
. 2022 Sep;
17(9):e0274283.
PMID: 36137152
In recent years, new direct-acting antivirals for hepatitis C virus (HCV) have been approved, but hepatitis C continues to pose a threat to human health. It is important to develop...
3.
Kondo T, Yamamoto T, Okayama K, Narumi H, Inoue H
Sci Rep
. 2022 Mar;
12(1):2690.
PMID: 35236875
Microbial flora is investigated to be related with neuropathological conditions in Alzheimer's disease (AD), and is attracting attention as a drug discovery resource. However, the relevance between the soil microbiota...
4.
Tsuge M, Uchida T, Hiraga N, Kan H, Makokha G, Abe-Chayama H, et al.
Antimicrob Agents Chemother
. 2017 Apr;
61(6).
PMID: 28373196
Although nucleot(s)ide analogues and pegylated interferon alpha 2a (PEG-IFN-α2a) can suppress hepatitis B virus (HBV) replication, it is difficult to achieve complete HBV elimination from hepatocytes. A novel site-specific pegylated...
5.
Iwamura T, Narumi H, Suzuki T, Yanai H, Mori K, Yamashita K, et al.
Cancer Sci
. 2017 Jan;
108(4):581-589.
PMID: 28129467
Malignant ascites manifests as an end-stage event during the progression of a number of cancers and lacks a generally accepted standard therapy. Interferon-β (IFN-β) has been used to treat several...
6.
Ishii M, Koyama A, Iseki H, Narumi H, Yokoyama N, Kojima N
Int Immunopharmacol
. 2010 Jun;
10(9):1041-6.
PMID: 20584630
Administration of oligomannose-coated liposomes (OMLs) in mice can induce Th1 immune responses against antigens entrapped in the OMLs. In the present study, we investigated the anti-allergic effect of treatment with...
7.
Sone S, Izawa A, Narumi H, Kajita A, Tanabe J, Taguchi F
Hepatol Res
. 2007 Feb;
37(2):121-6.
PMID: 17300707
Aim: To determine the differences in efficacy between therapy using IFN-beta and ribavirin, and using IFN-alpha and ribavirin. Methods: We studied the effect of combination therapy consisting of IFN-beta and...
8.
Teramura Y, Okamura Y, Takeoka S, Tsuchiyama H, Narumi H, Kainoh M, et al.
Biochem Biophys Res Commun
. 2003 Jun;
306(1):256-60.
PMID: 12788097
The recombinant fragment of the platelet membrane glycoprotein Ia/IIa (rGPIa/IIa) was conjugated to the polymerized albumin particles (polyAlb) with the average diameter of 180 nm. The intravenous administration of rGPIa/IIa-polyAlb...